Why Immutep Limited Stock Popped Today

Why Immutep Limited Stock Popped Today
Prosper Junior Bakiny, The Motley Fool
·2 min read

Immutep Limited reported that the U.S. Food and Drug Administration (FDA) granted the Fast Track designation to eftilagimod alpha in the treatment of recurring or metastatic head and neck squamous cell carcinoma (HNSCC). The Fast Track designation is given to drugs that fill an unmet medical need to expedite their development and approval. It ensures that the company in question and the FDA will work closely together at every step of the process.